In trading on Thursday, shares of Helios Advantage Income Fund (HAV) crossed below their 200 day moving average of $9.29, changing hands as low as $9.02 per share. Helios Advantage Income Fund shares are currently trading down about 2.7% on the day. The chart below shows the one year performance of HAV shares, versus its 200 day moving average:Looking at the chart above, HAV's low point in its 52 week range is $7.87 per share, with $9.90 as the 52 week high point — that compares with a last trade of $9.10. According to the ETF Finder at ETF Channel, HAV makes up 2.31% of the PowerShares International BuyBack Achievers Portfolio ETF ( IPKW) which is trading lower by about 0.9% on the day Thursday.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement
Let's look closer at the charts and indicators of ABBV.
2 Enigmatic Indices, Intriguing Oil, and Planet Fitness Slouches: Market Recon
Plus, a look at Ulta Beauty and a possible options play in the retailer.
Take-Two Interactive Looks Better on the Charts Than Activision Blizzard
Let's check out the charts of TTWO this morning.
Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20
U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.
Allergan Agrees to $63 Billion Takeover From AbbVie in Blockbuster Pharma Deal
Allergan shares surge in premarket trading Tuesday after it agreed to a $63 billion takeover from biopharmaceutical group AbbVie.